Differences in adherence to Osteoporosis Regimens: A 2-year analysis of a population treated under specific guidelines

Clinical Therapeutics

Volumn 35, Issue 7, 2013, Pages 1005-1015

  Cheng, Tien Tsai ^a   Yu, Shan Fu ^a   Hsu, Chung Yuan ^a   Chen, Sung Hsiung ^a   Su, Ben Yu Jih ^a   Yang, Tsong Shing ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Adherence; Guideline; Osteoporosis; Taiwan

Indexed keywords

ALENDRONIC ACID; CALCITONIN; MIACALCICS; RALOXIFENE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MEDICATION POSSESSION RATE; OSTEOPOROSIS; PARAMETERS; PATIENT COMPLIANCE; PERSISTENCE RATIO; PRACTICE GUIDELINE; RISK FACTOR; STATISTICAL ANALYSIS;

ADHERENCE; GUIDELINE; OSTEOPOROSIS; TAIWAN;

ADULT; AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS; RALOXIFENE; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84880507308     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.05.019     Document Type: Article

References (34)

1. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282:637-645.
2. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348:1535-1541.
3. Chesnut C.H., Silverman S., Andriano K., et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. PROOF Study Group. Am J Med 2000, 109:267-276.
4. Andrade S.E., Walker A.M., Gottlieb L.K., et al. Discontinuation of antihyperlipidemic drugs-do rates reported in clinical trials reflect rates in primary care settings?. N Engl J Med 1995, 332:1125-1131.
5. Lo J.C., Pressman A.R., Omar M.A., Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 2006, 17:922-928.
6. Cotte F.E., Mercier F., De Pouvourville G. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis. Clin Ther 2008, 30:2410-2422.
7. Siris E.S., Harris S.T., Rosen C.J., et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006, 81:1013-1022.
8. Downey T.W., Foltz S.H., Boccuzzi S.J., et al. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J 2006, 99:570-575.
9. Ziller V., Wetzel K., Kyvernitakis I., et al. Adherence and persistence in patients with postmenopausal osteoporosis treated with raloxifene. Climacteric 2011, 14:228-235.
10. Penning-van Beest F.J., Goettsch W.G., Erkens J.A., Herings R.M. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 2006, 28:236-242.
11. Briesacher B.A., Andrade S.E., Harrold L.R., et al. Adherence and occurrence of fractures after switching to once-monthly oral bisphophonates. Pharmacoepidemiol Drug Saf 2010, 19:1233-1240.
12. Halpern R., Becker L., Iqbal S.U., et al. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm 2011, 17:25-39.
13. Siris E.S., Pasquale M.K., Wang Y., Watts N.B. Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001-2008. J Bone Miner Res 2011, 26:3-11.
14. National Osteoporosis Foundation: Clinician's Guide to Prevention and Treatment of Osteoporosis. Accessed August 30, 2008. http://www.nof.org/professionals/NOF_Clinicians_Guide.pdf.
15. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum. 2001;44:1496-1503.
16. Cramer J.A., Roy A., Burrell A., et al. Medication compliance and persistence: terminology and definitions. Value Health 2008, 11:44-47.
17. Kothawala P., Badamgarav E., Ryu S., et al. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 2007, 82:1493-1501.
18. Cramer J.A., Amonkar M.M., Hebborn A., Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005, 21:1453-1460.
19. Ideguchi H., Ohno S., Hattori H., Ishigatsubo Y. Persistence with bisphosphonate therapy including treatment courses with multiple sequential bisphosphonates in the real world. Osteoporos Int 2007, 18:1421-1427.
20. McCombs J.S., Thiebaud P., McLaughlin-Miley C., Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004, 48:271-287.
21. Weycker D., Macarios D., Edelsberg J., Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006, 17:1645-1652.
22. Warriner A.H., Curtis J.R. Adherence to osteoporosis treatments: room for improvement. Curr Opin Rheumatol 2009, 21:356-362.
23. Papaioannou A., Kennedy C.C., Dolovich L., et al. Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 2007, 24:37-55.
24. Silverman S., Gold D.T. Compliance and persistence with osteoporosis medications: a critical review of the literature. Rev Endocrine Metab Disord 2010, 11:275-280.
25. Silverman S.L. Osteoporosis therapies: evidence from health-care databases and observational population studies. Calcif Tissue Int 2010, 87:375-384.
26. Soong Y.K., Tsai K.S., Huang H.Y., et al. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan. Osteoporos Int 2013, 24:511-521.
27. Thiebaud P., Patel B.V., Nichol M.B., Berenbeim D.M. The effect of switching on compliance and persistence: the case of statin treatment. Am J Manag Care 2005, 11:670-674.
28. FRAX WHO fracture risk assessment tool. Accessed October 5, 2010. http://www.shef.ac.uk/FRAX/.
29. Leslie W.D., Lix L.M., Johansson H., et al. Does osteoporosis therapy invalidate FRAX for fracture prediction?. J Bone Miner Res 2012, 27:1243-1251.
30. Dawson-Hughes B., Looker A.C., Tosteson A.N., et al. The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int 2009, 21:41-52.
31. Confavreux C.B., Canoui-Poitrine F., Schott A.M., et al. Persistence at 1 year of oral antiosteoporotic drugs: a prospective study in a comprehensive health insurance database. Eur J Endocrinol 2012, 166:735-741.
32. Turbí C., Herrero-Beaumont G., Acebes J.C., et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 2004, 26:245-256.
33. Watts N.B., Worley K., Solis A., et al. Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. J Manag Care Pharm 2004, 10:142-151.
34. Cadarette S.M., Katz J.N., Brookhart M.A., et al. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med 2008, 148(9):637-646.